CO6640224A2 - Inhibidores de la actividad de la proteína tirosina quinasa - Google Patents

Inhibidores de la actividad de la proteína tirosina quinasa

Info

Publication number
CO6640224A2
CO6640224A2 CO12207317A CO12207317A CO6640224A2 CO 6640224 A2 CO6640224 A2 CO 6640224A2 CO 12207317 A CO12207317 A CO 12207317A CO 12207317 A CO12207317 A CO 12207317A CO 6640224 A2 CO6640224 A2 CO 6640224A2
Authority
CO
Colombia
Prior art keywords
tyrosine kinase
inhibitors
kinase protein
protein activity
compounds
Prior art date
Application number
CO12207317A
Other languages
English (en)
Spanish (es)
Inventor
Yohei Yuki
Masashi Kishida
Arkadii Vaisburg
Franck Raeppel
Stephane Raeppel
Stephen Claridge
Lijie Zhan
Frederic Gaudette
Michael Mannion
Norifumi Sato
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of CO6640224A2 publication Critical patent/CO6640224A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CO12207317A 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa CO6640224A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16

Publications (1)

Publication Number Publication Date
CO6640224A2 true CO6640224A2 (es) 2013-03-22

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
CO12207317A CO6640224A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa
CO12207310A CO6630193A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa seleccionada

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO12207310A CO6630193A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa seleccionada

Country Status (19)

Country Link
US (3) US8455484B2 (OSRAM)
EP (2) EP2563794A4 (OSRAM)
JP (2) JP2013525286A (OSRAM)
KR (2) KR20130100234A (OSRAM)
CN (2) CN102947315A (OSRAM)
AR (2) AR080871A1 (OSRAM)
AU (2) AU2011241422B2 (OSRAM)
CA (2) CA2796054A1 (OSRAM)
CO (2) CO6640224A2 (OSRAM)
EA (2) EA201291052A1 (OSRAM)
MX (2) MX2012012032A (OSRAM)
MY (1) MY157319A (OSRAM)
NZ (2) NZ602948A (OSRAM)
PH (2) PH12012502073A1 (OSRAM)
SG (2) SG184883A1 (OSRAM)
TW (2) TW201204734A (OSRAM)
UA (1) UA108878C2 (OSRAM)
WO (2) WO2011127567A1 (OSRAM)
ZA (2) ZA201207482B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008293038B2 (en) * 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
EP2332536A1 (en) * 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
SG184883A1 (en) * 2010-04-16 2012-11-29 Methylgene Inc Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1957498B1 (en) * 2005-05-20 2017-02-15 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
AU2008293038B2 (en) 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
EP2332536A1 (en) * 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
SG184883A1 (en) * 2010-04-16 2012-11-29 Methylgene Inc Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity

Also Published As

Publication number Publication date
CN103025740B (zh) 2015-07-01
AU2011241422B2 (en) 2015-05-07
CN102947315A (zh) 2013-02-27
SG184883A1 (en) 2012-11-29
CA2796008A1 (en) 2011-10-20
TW201204735A (en) 2012-02-01
MY157319A (en) 2016-05-31
US20110257100A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
CO6630193A2 (es) 2013-03-01
AR080875A1 (es) 2012-05-16
TW201204734A (en) 2012-02-01
NZ602954A (en) 2014-11-28
MX2012012031A (es) 2012-12-17
EP2563794A1 (en) 2013-03-06
US8455484B2 (en) 2013-06-04
AU2011241420B2 (en) 2015-04-16
EA201291055A1 (ru) 2013-09-30
PH12012502070A1 (en) 2015-05-08
JP2013523846A (ja) 2013-06-17
ZA201207482B (en) 2013-09-25
MX2012012032A (es) 2012-12-17
SG184882A1 (en) 2012-11-29
WO2011127565A1 (en) 2011-10-20
AU2011241422A1 (en) 2012-11-01
EA201291052A1 (ru) 2013-04-30
US8906852B2 (en) 2014-12-09
JP2013525286A (ja) 2013-06-20
EP2563795A1 (en) 2013-03-06
KR20130058006A (ko) 2013-06-03
AR080871A1 (es) 2012-05-16
CN103025740A (zh) 2013-04-03
WO2011127567A1 (en) 2011-10-20
CA2796054A1 (en) 2011-10-20
EP2563794A4 (en) 2013-12-04
ZA201207557B (en) 2013-06-26
US20110257175A1 (en) 2011-10-20
PH12012502073A1 (en) 2013-02-11
NZ602948A (en) 2014-09-26
EP2563795A4 (en) 2013-10-23
UA108878C2 (ru) 2015-06-25
US20140315801A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
CO6640224A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa
CO6290684A2 (es) Inhibidores de actividad de proteina tirosina quinasa
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX375194B (es) Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
CR20150490A (es) Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret)
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
DOP2014000253A (es) Inhibidores del nampt
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2010001813A (es) Metodos y composiciones para el tratamiento de canceres.
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
CR20150029A (es) Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular

Legal Events

Date Code Title Description
FG Application granted